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ABSTRACT
Objectives: To evaluate changes in influenza
vaccination rates in healthy and at-risk children
following the implementation of the UK’s childhood
influenza immunisation programme.
Design: Observational cohort study before and after
initiation of the UK’s childhood influenza immunisation
programme over three influenza seasons (2012–2013,
2013–2014 and 2014–2015) using data from the
Clinical Practice Research Datalink (CPRD).
Setting: More than 500 primary care practices in
the UK.
Population: All individuals aged 2–17 years on 1
September, with at least 12 months of medical history
documented in CPRD were retained in the analysis.
Intervention: Starting in 2013–2014, all children aged
2 and 3 years were offered influenza vaccination
through general practice, and primary school-aged
children were offered influenza vaccination in selected
counties in England (described as pilot regions). The
vaccination programme was extended to all children
aged 4 years in England in 2014–2015.
Main outcome measure: Cumulative vaccination rate
from 1 September to 28 February of the next calendar
year as assessed by a time-to-event statistical model
(vaccination uptake). Age group, sex, region and type of
high-risk medical condition were assessed as predictors.
Results: Vaccination uptake increased considerably from
2012–2013 to 2013–2014 in targeted children aged
2–3 years, both in children with a high-risk medical
condition (from 40.7% to 61.1%) and those without
(from 1.0% to 43.0%). Vaccination rates increased also,
though less markedly, in older children. In 2014–2015,
vaccination rates remained higher than 40% in healthy
children aged 2–3 years, although they decreased slightly
from 2013–2014 (from 43.0% to 41.8%). Vaccination
rates in older healthy children continued to increase,
driven primarily by an increase in children aged 4 years
to 31.3% in 2014–2015.
Conclusions: The introduction of a universal childhood
vaccination policy in the UK increased vaccination rates
for targeted children, including those with high-risk
conditions.
INTRODUCTION
Inﬂuenza immunisation programmes have
traditionally targeted those with medical con-
ditions that predispose them to a high risk of
inﬂuenza complications. In the UK, immun-
isation programmes provided by the National
Health Service have also targeted the elderly;
in 2000, the programme was extended to
include everyone aged over 65 years. This
programme has been successful in reducing
inﬂuenza-related morbidity and mortality.1 In
2013, the UK initiated the roll-out of a uni-
versal childhood vaccination programme for
healthy and at-risk children, with live attenu-
ated inﬂuenza vaccine (LAIV), based on the
recommendation of the Joint Committee on
Strengths and limitations of this study
▪ The Clinical Practice Research Datalink (CPRD)
database of longitudinal general practice medical
records allows repeated measurements of influ-
enza vaccination uptake across seasons in a
large and representative population in a primary
care setting.
▪ The database also allows the identification of
patients with high-risk conditions.
▪ It is possible that influenza vaccinations adminis-
tered outside of general practices—for instance,
as part of school-based programmes—are not
completely captured in CPRD, resulting in an
underestimation of the vaccination rate.
▪ This is the first analysis of its type, investigating
vaccination rates in UK children and adolescents
with and without high-risk conditions after the
implementation of a national vaccination
programme.
▪ The findings of this study can aid influenza vac-
cination policy decision-making in the UK and
other countries considering the implementation
of childhood influenza vaccination programmes.
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Vaccination and Immunisation.2 In the ﬁrst season of
the programme in 2013–2014, children aged 2 and
3 years were offered inﬂuenza vaccination, to be admi-
nistered by their primary care practice. This programme
was extended to all children aged 4 years in the 2014–
2015 season. In addition, a number of pilot schemes
were undertaken in primary and secondary schools
across the UK, in particular in Scotland and Northern
England, to evaluate the programme in older age
groups.3 4
With any new national immunisation programme, it is
important to quantify the uptake of the vaccine for the
overall target population,5 6 and to evaluate whether
coverage necessary for indirect protective effects has
been achieved following widespread introduction.
Here, we report the results of an observational cohort
study that estimates changes in inﬂuenza vaccination
rates in UK children with and without high-risk medical
conditions, after the implementation of the national
immunisation programme, using data from the Clinical
Practice Research Datalink (CPRD).
METHODS
This observational cohort study was conducted during
three inﬂuenza seasons, before the implementation of
the extended childhood programme (2012–2013) and
in its ﬁrst (2013–2014) and second year (2014–2015).
All individuals aged 2–17 years on 1 September 2012
(season 2012–2013), 1 September 2013 (season 2013–
2014) and 1 September 2014 (season 2014–2015) with
at least 12 months of medical history documented in
CPRD were retained in the analysis. These individuals
were then followed up for 6 months to estimate the
inﬂuenza vaccination rate for the season.
CPRD maintains a database of anonymised longitu-
dinal medical records from primary care from over 500
practices in the UK. CPRD is considered to be broadly
representative of the UK population.7 Demographic,
clinical, referral, therapy and immunisation records were
used in this analysis. The study protocol was approved by
the Independent Scientiﬁc Advisory Committee (ISAC)
(Protocol 14_062A). Data were extracted from the data-
bases released by CPRD in July 2015.
Vaccine recipients as well as the vaccination date were
identiﬁed from immunisation, clinical and therapy
records. High-risk groups recommended for vaccination
were deﬁned using the operational speciﬁcations pub-
lished by PRIMIS at the University of Nottingham.8 All
diagnosis codes since enrolment in CPRD were queried.
The cumulative vaccination rate was analysed from
1 September to 28 February of the next calendar year
for each season using Cox proportional hazard models.
These are semiparametric time-to-event models that do
not make any assumptions about vaccination uptake
over the course of an inﬂuenza season but assume that
the effects of the predictor variables on vaccination
uptake are constant over time and independent.
Individuals were censored when the general practi-
tioner/practice stopped contributing to CPRD, when
the child left the practice, or when the child died,
whichever happened ﬁrst.
Time to vaccination was ﬁtted by a multivariable pro-
portional hazards (Cox’s) model that included season,
sex, region and type of high-risk condition as potential
predictors or confounders. Interaction terms between
season and the three other covariates were also intro-
duced in the model to assess any effect modiﬁcation by
season. The models were ﬁtted separately for each age
group (2–3, 4–8 and 9–17 years) as the speciﬁcations of
the national vaccination programme were a function of
age and evolved over the three seasons.
All analyses were conducted with SAS V.9.3 (SAS
Institute, North Carolina, USA).
Participant involvement
This was a non-interventional study using existing data
from CPRD. No proactive data collection from the parti-
cipants was required.
RESULTS
A total of 850 423, 792 257 and 712 143 children and
adolescents aged 2–17 years were documented in CPRD
on 1 September each year (2012–2014). In total,
794 138, 735 136 and 660 216 children and adolescents
were retained in the analysis for the 2012–2013, 2013–
2014 and 2014–2015 seasons, respectively, after exclusion
of participants with <12 months of medical history
(56 285, 57 121 and 51 927, respectively).
The population demographics are presented in table 1.
Between 6% and 7% of all children presented with at
least one high-risk condition in the 2012–2013, 2013–
2014 and 2014–2015 seasons (53 475 children in 2012–
2013, 48 254 in 2013–2014 and 41 940 in 2014–2015
season). The most frequent high-risk condition was
chronic respiratory diseases, including asthma.
The vaccination uptake in children aged 2–3 years
increased from 40.7% in 2012–2013 to 61.1% in 2013–
2014 for those with a high-risk condition and from 1.0%
to 43.0% for those without a high-risk condition (table 2).
It then decreased slightly in 2014–2015 to 57.0% among
children aged 2–3 years with high-risk conditions and to
41.8% in children without high-risk conditions.
In 2013–2014, vaccination rates also increased among
older children and adolescents with high-risk conditions,
from 41.3% to 45.1% in children aged 4–8 years and
from 40.8% to 42.6% in children aged 9–17 years.
A similar increase was seen in older children and adoles-
cents without high-risk conditions, from 1.1% to 4.3% in
children aged 4–8 years and from 1.3% to 3.3% in chil-
dren aged 9–17 years.
In 2014–2015, vaccination rates in older children and
adolescents without high-risk conditions continued to
increase from 4.3% in 2013–2014 to 12.7% in 2014–2015,
in children aged 4–8 years—primarily driven by an
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increase in vaccination rates to 31.3% in children aged
4 years—and from 3.3% to 4.6% in children aged 9–17
years. Vaccination rates in children with high-risk condi-
tions remained stable at over 40% and above 2012–2013
rates: 45.1% and 44.2% in children aged 4–8 years, 42.6%
and 42.2% in children aged 9–17 years in 2013–2014 and
2014–2015, respectively. The small observed decreases
from 2013–2014 to 2014–2015 were statistically non-
signiﬁcant. Vaccination rate by high-risk medical condition
is also shown in ﬁgure 1.
Observed vaccination rates in boys and girls were very
similar before adjustment for other covariates, but there
were important differences between regions, with the
highest vaccination rates in Scotland or Northern
Ireland and the lowest ones in London.
Adjusted analyses (tables 3 and 4) conﬁrm increases
in vaccination rates from season 2012–2013 to seasons
2013–2014 and 2014–2015 in all age groups and in chil-
dren with or without high-risk medical conditions.
Compared with England/South, which was chosen as the
reference region because of its larger study population,
the adjusted hazard ratio (HR) of inﬂuenza vaccination
were higher among children aged 2 and 3 years in
Scotland and Northern Ireland. The higher HRs also
observed in children 4 years and older in Scotland and
England/North probably point to the impact of local
school vaccination programmes. Girls aged 9–17 years,
with or without high-risk conditions, were more
frequently vaccinated than boys in the same age group,
while a difference in the opposite direction—higher vac-
cination rate in boys—was observed in healthy children
aged 4–8 years. Among children with high-risk medical
conditions, those with diabetes were more likely to be
vaccinated than children with chronic respiratory
disease, while children with chronic heart disease or
chronic neurological diseases were less likely to be vacci-
nated, irrespective of the age group. HRs of the predic-
tors of vaccination rate, age group and season for
children without and with high-risk medical conditions
can be found in online supplementary tables A and B,
respectively.
DISCUSSION
Statement of principal findings
The roll-out of the UK’s childhood inﬂuenza immunisa-
tion programme in 2013–2014, which targeted all chil-
dren aged 2–3 years and included pilot schemes in older
children and adolescents, increased the vaccination rate
in children aged 2–3 years without high-risk conditions
from 1% to over 40% (HR of 59.9). Vaccination rates
also increased in children aged 2 and 3 years with high-
risk conditions and in older children as well, with or
without high-risk conditions, though the increase was
less marked than in children aged 2–3 years. Vaccination
rates in 2014–2015 remained higher than 40% in
Table 1 Description of the study population
Season 2012–2013
n=794 138
Season 2013–2014
n=735 136
Season 2014–2015
n=660 216
Age (years)
2–3 13% (99 855) 13% (93 161) 13% (83 241)
4–8 31% (248 486) 31% (232 735) 32% (211 204)
9–17 56% (445 797) 56% (409 240) 55% (365 771)
Sex
Male 51% (406 251) 51% (375 999) 51% (337 454)
Female 49% (387 887) 49% (359 137) 49% (322 762)
Region
England/North 14% (114 636) 14% (102 314) 12% (76 849)
England/Midlands 18% (147 158) 16% (121 547) 15% (100 850)
England/South 32% (253 833) 32% (232 379) 32% (215 025)
England/London 12% (94 681) 13% (97 368) 13% (83 585)
Northern Ireland 4% (28 189) 4% (28 090) 4% (28 204)
Scotland 11% (85 423) 12% (85 931) 13% (84 993)
Wales 9% (70 218) 9% (67 507) 11% (70 710)
High-risk condition
Chronic respiratory disease (including asthma) 5% (40 052) 5% (35 561) 5% (30 484)
Chronic heart disease 1% (6892) 1% (6511) 1% (5943)
Chronic kidney disease <1% (412) <1% (385) <1% (356)
Chronic liver disease <1% (232) <1% (213) <1% (183)
Chronic neurological disease <1% (3612) <1% (3384) <1% (3031)
Diabetes <1% (2052) <1% (1969) <1% (1740)
Immunosuppression <1% (1483) <1% (1427) <1% (1301)
Other high-risk condition <1% (391) <1% (298) <1% (236)
Any of the conditions above 7% (53 475) 7% (48 254) 6% (41 940)
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Table 2 Cumulative vaccination rate by age category (point estimate in % and 95% CI)
Children at risk Other children
2012–2013 2013–2014 2014–2015 2012–2013 2013–2014 2014–2015
Total population aged 2–17 years 41.0 (40.5 to 41.5) 44.4 (43.9 to 44.8) 43.5 (43.0 to 44.0) 1.2 (1.1 to 1.2) 8.8 (8.7 to 8.8) 12.0 (12.0 to 12.1)
Age (years)
2–3 40.7 (38.9 to 42.5) 61.1 (59.2 to 63.1) 57.0 (55.0 to 59.0) 1.0 (0.9 to 1.0) 43.0 (42.7 to 43.3) 41.8 (41.4 to 42.1)
4–8 41.3 (40.5 to 42.1) 45.1 (44.3 to 46.0) 44.2 (43.2 to 45.1) 1.1 (1.1 to 1.1) 4.3 (4.2 to 4.4) 12.7* (12.6 to 12.9)
9–17 40.8 (40.3 to 41.3) 42.6 (42.1 to 43.2) 42.2 (41.6 to 42.8) 1.3 (1.2 to 1.3) 3.3 (3.2 to 3.3) 4.6 (4.5 to 4.6)
Sex
Male 40.6 (40.1 to 41.2) 44.0 (43.4 to 44.6) 43.2 (42.5 to 43.8) 1.2 (1.2 to 1.2) 8.8 (8.7 to 8.9) 12.1 (12.0 to 12.2)
Female 41.3 (40.7 to 42.0) 44.8 (44.1 to 45.5) 44.0 (43.2 to 44.7) 1.2 (1.1 to 1.2) 8.7 (8.6 to 8.8) 12.0 (11.9 to 12.1)
Region
England/North 42.1 (41.0 to 43.2) 47.3 (46.1 to 48.5) 45.4 (44.0 to 46.9) 1.1 (1.1 to 1.2) 11.4 (11.2 to 11.6) 11.8 (11.6 to 12.1)
England/Midlands 42.4 (41.4 to 43.4) 45.2 (44.4 to 45.9) 46.6 (45.4 to 47.9) 1.0 (0.9 to 1.0) 6.5 (6.3 to 6.6) 11.8 (11.6 to 12.0)
England/South 39.9 (39.2 to 40.7) 42.6 (41.8 to 43.4) 43.6 (42.8 to 44.4) 1.3 (1.3 to 1.4) 7.0 (6.8 to 7.1) 9.1 (9.0 to 9.3)
England/London 35.4 (34.1 to 36.7) 37.5 (36.3 to 38.8) 36.1 (34.7 to 37.6) 1.0 (0.9 to 1.1) 8.2 (8.0 to 8.4) 7.7 (7.5 to 7.9)
Northern Ireland 56.9 (56.7 to 57.0) 56.1 (55.8 to 56.3) 41.2 (41.0 to 41.4) 1.9 (1.7 to 2.1) 12.3 (11.9 to 12.7) 10.4 (10.0 to 10.8)
Scotland 44.8 (43.6 to 46.1) 51.0 (49.7 to 52.3) 48.6 (47.3 to 50.0) 1.2 (1.1 to 1.3) 13.3 (13.1 to 13.6) 25.8 (25.5 to 26.1)
Wales 34.0 (32.7 to 35.2) 38.5 (37.1 to 39.8) 39.1 (37.8 to 40.5) 1.1 (1.0 to 1.2) 8.8 (8.5 to 9.0) 10.2 (10.0 to 10.4)
High-risk condition
Chronic respiratory disease 42.5 (42.0 to 43.0) 46.0 (45.4 to 46.5) 45.2 (44.6 to 45.7)
Chronic heart disease 30.8 (29.7 to 31.9) 36.0 (34.8 to 37.2) 36.0 (34.8 to 37.3)
Chronic kidney disease 38.7 (33.9 to 43.5) 37.8 (32.9 to 42.7) 33.2 (28.2 to 38.2)
Chronic liver disease 44.7 (44.1 to 45.4) 48.0 (47.3 to 48.6) 45.1 (44.4 to 45.9)
Chronic neurological disease 32.6 (31.1 to 34.2) 36.1 (34.5 to 37.8) 34.9 (33.2 to 36.7)
Diabetes 66.0 (63.9 to 68.1) 65.9 (63.7 to 68.0) 64.1 (61.8 to 66.4)
Immunosuppression 46.9 (44.3 to 49.4) 48.1 (45.4 to 50.7) 45.4 (42.6 to 48.2)
*Vaccination rates of 31.3% (30.8% to 31.8%), 8.3% (8.0% to 8.6%), 8.1% (7.8% to 8.4%), 8.0% (7.7% to 8.2%) and 7.6% (7.4% to 7.9%) in children aged 4, 5, 6, 7 and 8 years, respectively.
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healthy children aged 2–3 years and were increased in
older children compared with the 2012–2013 season.
The extension of the programme to children aged
4 years in 2014–2015 likely contributed to the increased
uptake in children aged 4–8 years relative to the 2012–
2013 season. Vaccination rates observed in 2014–2015 in
older children with a high-risk medical condition
remained stable and signiﬁcantly higher than in 2012–
2013.
Our analysis demonstrated that a universal immunisa-
tion policy for inﬂuenza can increase vaccination rates
in the overall target population and in key subgroups,
such as those with high-risk conditions in whom vaccin-
ation was already recommended.
Strengths and weaknesses of the study
The CPRD database of longitudinal general practice
medical records allows repeated measurements of vac-
cination uptake across seasons in a large and representa-
tive population in a primary care setting. The database
also allows the identiﬁcation of patients with high-risk
conditions.
It is possible that vaccinations administered outside of
general practices—for instance, as part of school-based
programmes—are not completely captured in CPRD,
resulting in an underestimation of the inﬂuenza vaccin-
ation rate. However, given the observation of higher vac-
cination rates in regions that implemented widespread
school-based vaccination, it is unlikely that this effect is
large.
Strengths and weaknesses in relation to other studies,
discussing important differences in results
The vaccination rates estimated in this study are consist-
ent with public health agency reports in the UK that
used different data sources such as ImmForm and the
Royal College of General Practitioners database.9 Our
study is also in agreement with the 52.5% coverage in
England reported by Public Health England for the
2013–2014 season,4 which is higher than the coverage
Figure 1 Vaccination rate in children with high-risk medical conditions aged 2–17 years in the 2012–2013, 2013–2014 and
2014–2015 seasons.
Table 3 HRs of the predictors of influenza vaccination rate among children and adolescents without high-risk condition;
presentation by age group
2–3 year olds 4–8 year olds 9–17 year olds
Estimate 95% CI p Value Estimate 95% CI p Value Estimate 95% CI p Value
Season
2012–2013 1.00* 1.00* 1.00*
2013–2014 59.91 (56.13 to 64.04) 4.01 (3.84 to 4.20) 2.55 (2.47 to 2.64)
2014–2015 53.97 (50.56 to 57.69) <0.001 12.62 (12.11 to 13.16) <0.001 3.50 (3.39 to 3.61) <0.001
Sex <0.01† <0.001† 0.10†
Male 1.00* 1.00* 1.00*
Female 0.99 (0.98 to 1.01) 0.44 0.95 (0.94 to 0.97) <0.001 1.06 (1.04 to 1.08) <0.001
Region <0.001† <0.001† <0.001†
England/North 0.93 (0.90 to 0.95) 2.75 (2.66 to 2.84) 1.92 (1.84 to 2.00)
England/Midlands 0.92 (0.90 to 0.94) 1.14 (1.09 to 1.18) 1.68 (1.61 to 1.75)
England/South 1.00* 1.00* 1.00*
England/London 0.68 (0.66 to 0.70) 1.50 (1.44 to 1.56) 1.08 (1.03 to 1.13)
Northern Ireland 1.93 (1.87 to 2.00) 0.89 (0.83 to 0.96) 2.26 (2.14 to 2.39)
Scotland 1.21 (1.19 to 1.24) 5.18 (5.03 to 5.34) 4.53 (4.38 to 4.69)
Wales 0.82 (0.79 to 0.84) <0.001 0.91 (0.87 to 0.96) <0.001 2.74 (2.64 to 2.85) <0.001
*Reference group.
†p Value of the interaction term between season and each other predictor.
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reported for the USA in the same season (38% of chil-
dren vaccinated).10 Inﬂuenza vaccination rates for chil-
dren with high-risk medical conditions are not
uniformly reported and there are few comparable
studies in the literature. However, existing data suggest
very low uptake in those with high-risk medical condi-
tions in Europe,11–14 the USA15 and Canada16 in the
years before age-based universal vaccination recommen-
dations. A number of factors are known to contribute to
low inﬂuenza vaccination uptake, including individuals’
awareness of the seriousness of inﬂuenza,13 17 willing-
ness to accept medical advice,17 recommendation from
a healthcare worker,13 14 perception of vaccine safety14
and negative media coverage.14 These factors are also
likely to extend to parents making the decision as to
whether their child should receive the inﬂuenza vaccine.
The analyses carried out here are useful as they provide
a reference range for vaccination rates in children with
a universal policy in a European country, as well as
insight into some factors that may have affected vaccin-
ation uptake in the children with high-risk medical con-
ditions before the universal vaccination policy. The
increased uptake in children with chronic respiratory
diseases is particularly promising, as rates have failed to
increase in previous years in other targeted
programmes,17 demonstrating the value of a universal
programme on vaccination rates across different
segments of the population. However, the European
Council target vaccination rate of 75% among children
with chronic conditions18 has not yet been met in the
UK, despite the UK coming close to elderly vaccination
targets of 75%.14 Studies show that other countries in
Europe also struggle to meet the recommended vaccin-
ation rates,11–13 19 with a comprehensive survey of vaccin-
ation rates in the European Union, Norway and Iceland
between 2008 and 2011 estimating a vaccination rate of
32.9–71.7%.14
The effectiveness of the UK’s universal childhood im-
munisation programme on inﬂuenza-related morbidity
was not estimated as part of the analysis reported here,
but vaccinating primary school-aged children in pilot
areas during the 2014–2015 season resulted in signiﬁ-
cant and non-signiﬁcant reductions in a range of surveil-
lance indicators for the targeted age groups and wider
society (due to indirect protective effects).20
Meaning of the study: possible explanations and
implications for clinicians and policymakers
Seasonal inﬂuenza infection poses a signiﬁcant burden
to children, in particular to those with high-risk condi-
tions.21–24 As rates of vaccination in the childhood popu-
lation with chronic medical conditions have been low to
date,9 the increased uptake of the vaccine in high-risk
children during the 2013–2014 and 2014–2015 seasons
is encouraging. While the UK’s universal childhood
immunisation policy was justiﬁed based on the beneﬁts
of direct protection to all children and indirect beneﬁts
to the general population,1 2 it appears that this new
Table 4 HRs of the predictors of influenza vaccination rate among children and adolescents with high-risk medical
conditions; presentation by age group
2–3 year olds 4–8 year olds 9–17 year olds
Estimate 95% CI p Value Estimate 95% CI p Value Estimate 95% CI p Value
Season
2012–2013 1.00* 1.00* 1.00*
2013–2014 1.83 (1.69 to 1.97) 1.14 (1.10 to 1.19) 1.06 (1.04 to 1.09)
2014–2015 1.52 (1.40 to 1.65) <0.001 1.07 (1.04 to 1.12) <0.001 1.03 (1.01 to 1.06) <0.001
Sex 0.97† 0.84† 0.99†
Male 1.00* 1.00* 1.00*
Female 0.98 (0.92 to 1.04) 0.48 1.01 (0.98 to 1.04) 0.52 1.05 (1.03 to 1.07) <0.001
Region 0.04† <0.001† <0.001†
England/North 1.03 (0.93 to 1.13) 1.21 (1.15 to 1.27) 1.08 (1.04 to 1.11)
England/Midlands 1.05 (0.95 to 1.16) 1.13 (1.08 to 1.27) 1.07 (1.04 to 1.11)
England/South 1.00* 1.00* 1.00*
England/London 0.83 (0.74 to 0.93) 0.84 (0.79 to 0.88) 0.81 (0.78 to 0.85)
Northern Ireland 1.64 (1.41 to 1.90) 1.20 (1.12 to 1.29) 1.46 (1.40 to 1.53)
Scotland 1.14 (1.03 to 1.26) 1.15 (1.09 to 1.21) 1.14 (1.11 to 1.18)
Wales 0.89 (0.79 to 0.99) <0.001 0.80 (0.75 to 0.85) <0.001 0.88 (0.85 to 0.91) <0.001
High-risk condition 0.27† <0.01† 0.04†
Chronic respiratory disease 1.00* 1.00* 1.00*
Chronic heart disease 0.86 (0.80 to 0.92) 0.68 (0.64 to 0.71) 0.57 (0.54 to 0.59)
Chronic neurological disease 0.75 (0.67 to 0.85) 0.69 (0.65 to 0.74) 0.61 (0.58 to 0.64)
Diabetes 1.55 (1.17 to 2.00) 1.78 (1.62 to 1.94) 1.81 (1.74 to 1.88)
Other high-risk condition‡ 1.24 (1.08 to 1.40) <0.001 1.16 (1.09 to 1.24) <0.001 1.05 (1.01 to 1.09) <0.001
*Reference group.
†p Value of the interaction term between season and each other predictor.
‡Chronic kidney disease, chronic liver disease, immunosuppression or pregnancy.
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policy also increases vaccination coverage in high-risk
groups of the paediatric population. This ﬁnding sug-
gests that general awareness of the importance of inﬂu-
enza vaccination may have been raised as a result of the
childhood programme, either directly through the pro-
gramme materials or word of mouth. The increase in
vaccination rates in children with chronic respiratory dis-
eases such as asthma is particularly encouraging as
asthma is the most prevalent high-risk condition, as well
as one with a relatively high risk of complications from
inﬂuenza.22
Of note, the USA and Canada already recommend
universal inﬂuenza vaccination to those 6 months and
older; however, the Canadian recommendation has pro-
vincial funding only in certain provinces.25 26
Unanswered questions and future research
The UK’s childhood inﬂuenza immunisation pro-
gramme will be extended further to include older age
groups in the coming years.27 Whether the encouraging
increases in vaccination rates seen in the target age
group during the ﬁrst two seasons are replicated in
older age groups and over several consecutive seasons
will be determined as the programme is expanded.
Studies of future inﬂuenza seasons will also conﬁrm
whether vaccination rates will continue to increase in
those who have chronic medical conditions. Further
research that aims at disentangling the direct and indirect
effectiveness of inﬂuenza vaccination resulting from a high
vaccination rate in the paediatric population could also
help to validate and optimise national vaccination pro-
grammes. The implementation of the UK’s childhood
inﬂuenza immunisation programme provides a unique
opportunity to address these questions.
CONCLUSIONS
The introduction of a universal childhood inﬂuenza vac-
cination policy in the UK increased vaccination rates for
all children in the target population (2–3 years in 2013–
2014, 2–4 years in 2014–2015) and also improved vaccin-
ation rates in those with high-risk conditions.
Vaccination rates increased in older children as well,
whether they had a high-risk medical condition or not,
although the increase was less marked than in children
aged 2–3 years. The results from the ﬁrst two seasons of
the UK’s childhood inﬂuenza vaccination programme
demonstrate that a universal inﬂuenza vaccination policy
can increase uptake for targeted children, including
those with high-risk conditions who were previously
recommended.
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